 | • レポートコード：MRC2301B124 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、244ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医療 |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社の本調査レポートでは、2021年に9,882.63百万ドルであった世界の大腸がん治療薬市場規模が、2022年に10,347.35百万ドルになり、2027年には13,152.73百万ドルまで、年平均4.87%で成長すると予測しています。本レポートでは、大腸がん治療薬の世界市場について調査・分析し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、クラス別（化学療法、免疫療法）分析、種類別（BRAF/MEK阻害剤、EGFR阻害剤、免疫調節剤、血管内皮増殖因子 (VEGF) 阻害剤、その他）分析、流通チャネル別（病院薬局、小売薬局）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況など、以下の構成でお届けします。なお、本書には、3SBio、AbbVie Inc.、Amgen、Astellas Pharma Inc.、AstraZeneca、Bayer、BeiGene、Bristol-Myers Squibb、Celgene、Cernostics、Cerus Corporation、CHAIN Biotechnology、Daiichi Sankyo、DNALite Therapeutics, Inc.、Eli Lilly、Gilead Sciences、GlaxoSmithKline、Helix、Immunocore、Incyte Corp、Johnson & Johnson、Merck & Co., Inc.、Novartis AG、Pfizer Inc.、Roche Holding AG、Sanofi、Spectrum Pharmaceuticals, Inc.、Takedaなどの企業情報が含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の大腸がん治療薬市場規模：クラス別 - 化学療法における市場規模 - 免疫療法における市場規模 ・世界の大腸がん治療薬市場規模：種類別 - BRAF/MEK阻害剤の市場規模 - EGFR阻害剤の市場規模 - 免疫調節剤の市場規模 - BRAF/MEK阻害剤の市場規模 - その他種類の市場規模 ・世界の大腸がん治療薬市場規模：流通チャネル別 - 病院薬局チャネルの市場規模 - 小売薬局チャネルの市場規模 ・世界の大腸がん治療薬市場規模：地域別 - 南北アメリカの大腸がん治療薬市場規模 アメリカの大腸がん治療薬市場規模 カナダの大腸がん治療薬市場規模 ブラジルの大腸がん治療薬市場規模 ... - アジア太平洋の大腸がん治療薬市場規模 日本の大腸がん治療薬市場規模 中国の大腸がん治療薬市場規模 インドの大腸がん治療薬市場規模 韓国の大腸がん治療薬市場規模 台湾の大腸がん治療薬市場規模 ... - ヨーロッパ/中東/アフリカの大腸がん治療薬市場規模 イギリスの大腸がん治療薬市場規模 ドイツの大腸がん治療薬市場規模 インドの大腸がん治療薬市場規模 フランスの大腸がん治療薬市場規模 ロシアの大腸がん治療薬市場規模 ... - その他地域の大腸がん治療薬市場規模 ・競争状況 ・企業情報 |
The Global Colorectal Cancer Drugs Market size was estimated at USD 9,882.63 million in 2021 and expected to reach USD 10,347.35 million in 2022, and is projected to grow at a CAGR 4.87% to reach USD 13,152.73 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Colorectal Cancer Drugs to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Class, the market was studied across Chemotherapy and Immunotherapy. The Chemotherapy is further studied across 5-Fluorouracil (5-FU), Capecitabine (Xeloda), a pill that is changed into 5-FU once it gets to the tumor., Irinotecan (Camptosar), Oxaliplatin (Eloxatin), and Trifluridine and tipiracil (Lonsurf),. The Immunotherapy is further studied across CTLA-4 Inhibitor, KRAS Inhibitor, and PD-1 Inhibitors.
Based on Type, the market was studied across BRAF or MEK Inhibitors, Epidermal Growth Factor Receptor (EGFR) Inhibitors, Immunomodulators, Programmed Cell Death Protein 1/PD1 Ligand 1 (PD1/PDL1) Inhibitors, Tyrosine Kinase (TKI) Inhibitors, and Vascular Endothelial Growth Factor (VEGF) Inhibitors.
Based on Distribution Channel, the market was studied across Hospitals Pharmacies and Retail Pharmacies.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Colorectal Cancer Drugs market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Colorectal Cancer Drugs Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Colorectal Cancer Drugs Market, including 3SBio, AbbVie Inc., Amgen, Astellas Pharma Inc., AstraZeneca, Bayer, BeiGene, Bristol-Myers Squibb, Celgene, Cernostics, Cerus Corporation, CHAIN Biotechnology, Daiichi Sankyo, DNALite Therapeutics, Inc., Eli Lilly, Gilead Sciences, GlaxoSmithKline, Helix, Immunocore, Incyte Corp, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer Inc., Roche Holding AG, Sanofi, Spectrum Pharmaceuticals, Inc., and Takeda.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Colorectal Cancer Drugs Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Colorectal Cancer Drugs Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Colorectal Cancer Drugs Market?
4. What is the competitive strategic window for opportunities in the Global Colorectal Cancer Drugs Market?
5. What are the technology trends and regulatory frameworks in the Global Colorectal Cancer Drugs Market?
6. What is the market share of the leading vendors in the Global Colorectal Cancer Drugs Market?
7. What modes and strategic moves are considered suitable for entering the Global Colorectal Cancer Drugs Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increases identification and prevalence of colon cancer
5.1.1.2. Continuous drug development and investment in immunotherapies
5.1.2. Restraints
5.1.2.1. Potentially unmeasured side effects
5.1.3. Opportunities
5.1.3.1. Investment driven oncology segemnt
5.1.3.2. Introduction and increased availability of generics and biologics
5.1.4. Challenges
5.1.4.1. Affordability of patented drugs
5.2. Cumulative Impact of COVID-19
6. Colorectal Cancer Drugs Market, by Class
6.1. Introduction
6.2. Chemotherapy
6.3.1. 5-Fluorouracil (5-FU)
6.3.2. Capecitabine (Xeloda), a pill that is changed into 5-FU once it gets to the tumor.
6.3.3. Irinotecan (Camptosar)
6.3.4. Oxaliplatin (Eloxatin)
6.3.5. Trifluridine and tipiracil (Lonsurf),
6.3. Immunotherapy
6.4.1. CTLA-4 Inhibitor
6.4.2. KRAS Inhibitor
6.4.3. PD-1 Inhibitors
7. Colorectal Cancer Drugs Market, by Type
7.1. Introduction
7.2. BRAF or MEK Inhibitors
7.3. Epidermal Growth Factor Receptor (EGFR) Inhibitors
7.4. Immunomodulators
7.5. Programmed Cell Death Protein 1/PD1 Ligand 1 (PD1/PDL1) Inhibitors
7.6. Tyrosine Kinase (TKI) Inhibitors
7.7. Vascular Endothelial Growth Factor (VEGF) Inhibitors
8. Colorectal Cancer Drugs Market, by Distribution Channel
8.1. Introduction
8.2. Hospitals Pharmacies
8.3. Retail Pharmacies
9. Americas Colorectal Cancer Drugs Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Colorectal Cancer Drugs Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Colorectal Cancer Drugs Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis, By Key Player
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion
13. Company Usability Profiles
13.1. 3SBio
13.1.1. Business Overview
13.1.2. Key Executives
13.1.3. Product & Services
13.2. AbbVie Inc.
13.2.1. Business Overview
13.2.2. Key Executives
13.2.3. Product & Services
13.3. Amgen
13.3.1. Business Overview
13.3.2. Key Executives
13.3.3. Product & Services
13.4. Astellas Pharma Inc.
13.4.1. Business Overview
13.4.2. Key Executives
13.4.3. Product & Services
13.5. AstraZeneca
13.5.1. Business Overview
13.5.2. Key Executives
13.5.3. Product & Services
13.6. Bayer
13.6.1. Business Overview
13.6.2. Key Executives
13.6.3. Product & Services
13.7. BeiGene
13.7.1. Business Overview
13.7.2. Key Executives
13.7.3. Product & Services
13.8. Bristol-Myers Squibb
13.8.1. Business Overview
13.8.2. Key Executives
13.8.3. Product & Services
13.9. Celgene
13.9.1. Business Overview
13.9.2. Key Executives
13.9.3. Product & Services
13.10. Cernostics
13.10.1. Business Overview
13.10.2. Key Executives
13.10.3. Product & Services
13.11. Cerus Corporation
13.11.1. Business Overview
13.11.2. Key Executives
13.11.3. Product & Services
13.12. CHAIN Biotechnology
13.12.1. Business Overview
13.12.2. Key Executives
13.12.3. Product & Services
13.13. Daiichi Sankyo
13.13.1. Business Overview
13.13.2. Key Executives
13.13.3. Product & Services
13.14. DNALite Therapeutics, Inc.
13.14.1. Business Overview
13.14.2. Key Executives
13.14.3. Product & Services
13.15. Eli Lilly
13.15.1. Business Overview
13.15.2. Key Executives
13.15.3. Product & Services
13.16. Gilead Sciences
13.16.1. Business Overview
13.16.2. Key Executives
13.16.3. Product & Services
13.17. GlaxoSmithKline
13.17.1. Business Overview
13.17.2. Key Executives
13.17.3. Product & Services
13.18. Helix
13.18.1. Business Overview
13.18.2. Key Executives
13.18.3. Product & Services
13.19. Immunocore
13.19.1. Business Overview
13.19.2. Key Executives
13.19.3. Product & Services
13.20. Incyte Corp
13.20.1. Business Overview
13.20.2. Key Executives
13.20.3. Product & Services
13.21. Johnson & Johnson
13.21.1. Business Overview
13.21.2. Key Executives
13.21.3. Product & Services
13.22. Merck & Co., Inc.
13.22.1. Business Overview
13.22.2. Key Executives
13.22.3. Product & Services
13.23. Novartis AG
13.23.1. Business Overview
13.23.2. Key Executives
13.23.3. Product & Services
13.24. Pfizer Inc.
13.24.1. Business Overview
13.24.2. Key Executives
13.24.3. Product & Services
13.25. Roche Holding AG
13.25.1. Business Overview
13.25.2. Key Executives
13.25.3. Product & Services
13.26. Sanofi
13.26.1. Business Overview
13.26.2. Key Executives
13.26.3. Product & Services
13.27. Spectrum Pharmaceuticals, Inc.
13.27.1. Business Overview
13.27.2. Key Executives
13.27.3. Product & Services
13.28. Takeda
13.28.1. Business Overview
13.28.2. Key Executives
13.28.3. Product & Services
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing